<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">Lymphopenia occurred in all patients (grade 3/4 in 46 patients [96%]), with all evaluated lymphocyte subsets (CD3
 <sup>+</sup>, CD4
 <sup>+</sup>, CD8
 <sup>+</sup>, CD16
 <sup>+</sup>, CD20
 <sup>+</sup>, CD56
 <sup>+</sup>) showing reductions from baseline (Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>). Other common grade 3/4 hematologic toxicities included leukopenia (42%), neutropenia (35%), and thrombocytopenia (25%; Table 
 <xref rid="Tab2" ref-type="table">2</xref>). Febrile neutropenia occurred in six patients (13%). Grade 3/4 non-hematologic toxicities were uncommon. Adverse events that resulted in discontinuation occurred in 11 patients (23%; only Epstein-Barr virus [EBV]-associated lymphoma (
 <italic>n</italic> = 2) led to discontinuation in &gt; 1 patient). One patient in phase 2 died from disseminated intravascular coagulation and multiorgan failure, which was attributed to underlying disease and considered not related to forodesine.
</p>
